Wells Fargo’s Kindred Biosciences, Inc. KIN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-426,835
| Closed | -$3.92M | – | 7912 |
|
|
2021
Q2 | $3.92M | Buy |
426,835
+18,221
| +4% | +$106K | ﹤0.01% | 3078 |
|
|
2021
Q1 | $2.03M | Sell |
408,614
-57,424
| -12% | -$277K | ﹤0.01% | 3687 |
|
|
2020
Q4 | $2.01M | Buy |
466,038
+78,643
| +20% | +$320K | ﹤0.01% | 3495 |
|
|
2020
Q3 | $1.66M | Buy |
387,395
+92,114
| +31% | +$385K | ﹤0.01% | 3453 |
|
|
2020
Q2 | $1.33M | Buy |
295,281
+134,640
| +84% | +$602K | ﹤0.01% | 3591 |
|
|
2020
Q1 | $643K | Sell |
160,641
-6,358
| -4% | -$54K | ﹤0.01% | 3846 |
|
|
2019
Q4 | $1.42M | Sell |
166,999
-46,613
| -22% | -$364K | ﹤0.01% | 3609 |
|
|
2019
Q3 | $1.46M | Buy |
213,612
+31,332
| +17% | +$230K | ﹤0.01% | 3582 |
|
|
2019
Q2 | $1.52M | Sell |
182,280
-1,665
| -0.9% | -$14.4K | ﹤0.01% | 3562 |
|
|
2019
Q1 | $1.69M | Sell |
183,945
-8,453
| -4% | -$85.8K | ﹤0.01% | 3496 |
|
|
2018
Q4 | $2.11M | Buy |
192,398
+24,786
| +15% | +$312K | ﹤0.01% | 3222 |
|
|
2018
Q3 | $2.34M | Sell |
167,612
-154,294
| -48% | -$2.09M | ﹤0.01% | 3281 |
|
|
2018
Q2 | $3.43M | Sell |
321,906
-37,977
| -11% | -$370K | ﹤0.01% | 3016 |
|
|
2018
Q1 | $3.11M | Sell |
359,883
-6,852
| -2% | -$60.1K | ﹤0.01% | 3012 |
|
|
2017
Q4 | $3.46M | Buy |
366,735
+29,127
| +9% | +$228K | ﹤0.01% | 2912 |
|
|
2017
Q3 | $2.65M | Buy |
337,608
+7,206
| +2% | +$54.1K | ﹤0.01% | 3080 |
|
|
2017
Q2 | $2.84M | Buy |
330,402
+500
| +0.2% | +$3.59K | ﹤0.01% | 2915 |
|
|
2017
Q1 | $2.33M | Buy |
329,902
+3,550
| +1% | +$22.2K | ﹤0.01% | 3076 |
|
|
2016
Q4 | $1.39M | Buy |
326,352
+116,725
| +56% | +$565K | ﹤0.01% | 3452 |
|
|
2016
Q3 | $1.05M | Buy |
209,627
+206,638
| +6,913% | +$873K | ﹤0.01% | 3464 |
|
|
2016
Q2 | $11K | Buy |
2,989
+2,250
| +304% | +$8.27K | ﹤0.01% | 5646 |
|
|
2016
Q1 | $3K | Sell |
739
-148,946
| -100% | -$526K | ﹤0.01% | 5986 |
|
|
2015
Q4 | $509K | Buy |
149,685
+149,585
| +149,585% | +$694K | ﹤0.01% | 3919 |
|
|
2015
Q3 | $1K | Sell |
100
-1,437
| -93% | -$8.86K | ﹤0.01% | 6104 |
|
|
2015
Q2 | $10K | Buy |
1,537
+978
| +175% | +$6.94K | ﹤0.01% | 5824 |
|
|
2015
Q1 | $4K | Sell |
559
-3,634
| -87% | -$25K | ﹤0.01% | 5877 |
|
|
2014
Q4 | $32K | Sell |
4,193
-3,936
| -48% | -$33.4K | ﹤0.01% | 5189 |
|
|
2014
Q3 | $75K | Buy |
8,129
+3,343
| +70% | +$45.2K | ﹤0.01% | 4778 |
|
|
2014
Q2 | $90K | Buy |
+4,786
| New | +$81.3K | ﹤0.01% | 4729 |
|
Other funds holding KIN
Wells Fargo's KIN Position: Q3 2021 in Review
Wells Fargo sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 426,835 shares — an estimated $3.92M sold.
Wells Fargo first reported a position in KIN in Q2 2014 and held it in 29 quarters. The position peaked at $3.92M in Q2 2021. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.
- Wells Fargo reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
- Wells Fargo sold 426,835 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $3.92M.
- Wells Fargo first reported a position in Kindred Biosciences, Inc. in Q2 2014 and held it in 29 quarters.
- Wells Fargo's Kindred Biosciences, Inc. position peaked at $3.92M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.
Based on Wells Fargo's 13F filing for Q3 2021, filed 15 Nov 2021.